What is CAR-T therapy?
CAR-T is a treatment that involves altering a patient’s T-cells (a kind of lymphocyte that plays an essential role in the immune system) so that they actively destroy cancer cells. T-cells are first harvested from a patient’s blood and genetically modified to add a receptor that binds to a specific protein on the patient’s cancer cells, known as a chimeric antigen receptor (CAR). Then, the modified T-cells are cultured and expanded to obtain a large quantity of these modified tumor-specific cells, which are thereafter infused back into the patient.
What separates ICT from other companies?
In-house developed proprietary platform technology. Unlike other leading CAR-T companies which generally license their technologies from academic institutions, ICT’s discovery and development expertise resides within the company. This results in more effective and efficient product development.
Why is ICTCAR014 different?
ICTCAR014 is based on ICT’s first-in-class ArmoredCAR® T technology that combines conventional CAR-T technology with dominant negative PD-1 to block the PD-1/PD-L1 signaling pathway in order to inhibit T-cell exhaustion.
What cancers does ICT focus on?
Our current pipeline targets both liquid and solid tumors for treatment of non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, thyroid cancer, prostate cancer, and colorectal cancer.